Biogen Idec is a leading global biotechnological company, and is now expanding significantly in Denmark. As a result of an investment in billions, 250 new workers have joined the company during the last year. In total 430 employees are currently working for Biogen Idec in Denmark with among other things the production of pharmaceuticals for the treatment of multiple scleroses.
The Danish Minister for Trade and Investment visits Biogen Idec this Friday as part of a continuous effort to understand and improve conditions for foreign companies in Denmark. The objective is to improve framework conditions and the reception of foreign companies in Denmark.
Minister for Trade and Investment, Pia Olsen Dyhr, says:
- “Foreign companies represent only one per cent of all companies in Denmark, but employ 20 per cent of all employees in the private sector. This underlines the importance of attracting more foreign investments, and assuring that we do our utmost to offer foreign companies the best conditions here in Denmark.”
- “Our flexible and highly skilled workforce combined with efficient local and regional administration form an ideal platform for a company like Biogen Idec, and their expansion here in Denmark proves that our leading Medicon Valley is truly attractive for international biotech companies.”
Invest in Denmark and Copenhagen Capacity have assisted Biogen Idec all the way through, from benchmarks comparing Denmark to other European locations, to finding the right service providers and facilitating a dialogue with officials.
Biogen Idec is a global biotechnological company that develops, manufactures and markets biological products for the treatment of serious diseases with a focus on neurological disorders.
Biogen Idec’s CEO in Denmark Esther Alegria from the US explains:
- “Biogen Idec appreciates the highly skilled Danish workers, but also the Danish ability to cooperate, where employees are permanently contributing with improvements to the production process. We wouldn’t have come this far without a close and efficient cooperation with the local and regional administration and other public institutions as it happens here in Denmark.”
The company also emphasizes the Danish-Swedish Life Science cluster Medicon Valley as essential to the decision of choosing Denmark as location for their European production.
Biogen Idec made the decision to establish production facilities in Denmark in 2001, and has since built a large and sophisticated production facility in Hillerød, a long-term investment of around 700 million USD. Within the past year Biogen Idec has gone from 180 to 430 employees in Hillerød.
Biogen Idec was founded in USA in 1978 and is among the world's oldest and largest independent biotechnological companies. In 2011 Biogen Idec had revenues of more than 5 billion USD of which approx. 25 per cent are used in the research and development of new drugs. Biogen Idec is headquartered in Cambridge, Massachusetts, USA, and employs more than 5.000 employees globally.
Biogen Idec Manufacturing ApS in Hillerød is a strategically important part of Biogen Idec's global supply network. The international production site in Denmark is serving all markets in the world except the US and Canada with biological drugs for the treatment of multiple sclerosis.